This report from Life Science Intelligence provides the latest market data for the Global Tissue-based Heart Valves Market. Information covered by this report includes:
The global market for tissue heart valves is expected to reach an estimated $1.06 billion in 2020 and is projected to increase a CAGR (2020-2024) of 2.1%. The market includes tissue-based heart valves implanted in open heart surgery.
This report covers the impact of COVID-19 on tissue-based heart valve replacement procedures, including a recent forecast from 2020 to 2024. COVID-19 has also impacted leading competitors, such as Abbott, Medtronic, Edwards Lifesciences, LivaNova, CryoLife, and others. The report provides insights into trends, drivers, and limiters of the tissue-based heart valves market, as well as highlights potential opportunities.
Unlike mechanical heart valves, tissue-based heart valves are prone to structural valve deterioration. Therefore tissue-based heart valves are recommended primarily for elderly patients over the age of 70 years. The most recent generation of tissue-based heart valves are designed to offer better durability, hemodynamic performance, and ease in implantation.
Tissue-based heart valve replacement procedures were severally impacted as a result of COVID-19 related lockdowns and postponement of surgeries due to the profound pressure on healthcare resources. With the lockdown relaxation and subsequent opening of surgeries for critically ill patients, surgical procedure volumes are beginning to recover. Procedures which were canceled or postponed in 2020 are expected to be scheduled for 2021 and higher than normal procedure volumes are anticipated as hospitals ramp up resources and schedules to cover for the increased footfalls.